Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells Leukemia (2006) In the search for new treatment modalities necessary to eradicate minimal residual disease cells in acute myeloid leukemia (AML), immunotherapy provides an attractive option.
AML blasts have proven to be able to differentiate into dendritic cell (DC)-like leukemic antigen-presenting cells (APC) under serum-free, good clinical practise, conditions with the use of cytokines or calcium ionophores (CI), thereby providing the unique opportunity to generate APC harbouring the full range of potential, still unidentified tumor antigens. 1 In in vitro assays, cultured AML-DC have proven to fulfil all criteria necessary to elicit potent T-cell responses in vivo, such as migration towards lymph node associated chemokines, and induction of leukemiaspecific activation of cytotoxic T cells. [1] [2] [3] Here, we report the development of a predictive model for leukemic DC differentiation established in a large cohort of 154 patients. AML blast characteristics were studied in order to develop a model by which the outcome of an AML-DC culture can be established before culture, thus enabling selection of patients eligible for AML-DC vaccination protocols.
After informed consent, peripheral blood and bone marrow mononuclear cells of patients (n ¼ 154) diagnosed with AML in the period between 1999 and 2005 were cultured in presence of cytokines (n ¼ 147) and/or CI (n ¼ 108) as published previously (patient characteristics are shown in Table 1 ). 1 Briefly, fresh or thawed mononuclear cells were cultured in either Rosewell Park Memorial Institute 1640; 20% fetal calf serum or CellGro serum-free medium (CG); 100 U/ml penicillin and 100 mg/ml streptomycin. Differentiation towards DC was induced by the addition of a combination of cytokines: granulocyte-macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF-a), interleukin (IL)-3, stem cell factor (SCF), Flt3-L and IL-4 or CI A23187 and IL-4. Medium exchange with fresh medium supplemented with GM-CSF, TNF-a and IL-4, was routinely performed in case of an overgrown culture or medium exhaustion. After 2 and 14 days of culture, in presence of either CI or cytokines, respectively, cells were harvested. Prior and subsequent to culture phenotypic analysis of the following markers was performed by flowcytometry: CD34, CD14, CD45, CD40, CD54, CD80, CD86, CD83, CD1a, HLA-DR and CD120a as described previously. 1 Results were calculated as percentage positive cells as compared to the appropriate isotype control. Analysis of the results was carried out using CellQuest software (Becton Dickinson, San Jose, CA, USA). Apoptotic and necrotic cells, identified by syto-16 and 7-amino-actinomycin staining, as described previously, were excluded from the analysis. 1 A definition for AML-DC was formulated according to a working definition for DC proposed by Hart based on morphologic, immunophenotypic and functional properties of DC. 4 An AML-DC is characterized by a DC-like morphology with an eccentric position of the nucleus and large irregular shaped, elongated processes. In addition, AML-DC display a bright expression of CD40, increased or acquired expression of CD54, CD80, CD86, CD83 and HLA-DR and have an increased T cell stimulating capacity as compared to uncultured blasts. CD1a is not expressed by AML-DC. 1 Leukemic origin of AML-DC, as evaluated by fluorescent in situ hybridization analysis, has been demonstrated previously. 5 It might be argued that cultured DC are derived from normal monocytes or CD34 þ cells. However, this seems unlikely as approximately 60% of AML samples are myelo-and myelomonocytic leukemias, indicating malignant origin of the monocytes present in the AML sample. Some AML samples are evolved from myelodysplastic syndrome precursor cells, regarded in general as stem cell disease.
As published previously, percentage CD40 þ /CD86 þ cells were used to determine the amount of AML-DC. 6 Median AML-DC yield in the cytokine-based culture method was 12% (range: 0-70%). Defined by the median AML-DC yield, cultures resulting in X10% AML-DC were considered successful. As depicted in Table 1 , in 58% of AML patients (85/147), the cytokine-based culture method proved to be successful. The CI culture was successful in 61% (66/108) of AML-DC cultures (median yield: 16%, range: 0-90%). Overall, it is possible to generate functional AML-DC with either the cytokine-based culture method or the CI-based culture method in 66% (101/ 154) of AML patients. Opposite to what was expected, DC differentiation capacity of AML blasts is independent from the French-American-British subtype (Table 1 ). In particular, no significant differences were found between the myelomonocytic subtypes, M4 and M5, and other subtypes. Furthermore, age, sex, blast percentage, white blood cell count (WBC) nor cytogenetic risk groups differed between successful and unsuccessful AML-DC cultures (Table 1) . Previously, we identified the expression of TNFa-RI (CD120a) on AML blasts as predictor for cytokine-based AML-DC differentiation capacity. Moreover, also AML blasts expressing CD14 and CD86 were described to be able to differentiate into leukemic DC in presence of cytokines. 7 These observations could be confirmed in this large group of patients (CD120a; Spearman's r: 0.34; P ¼ 0.001, CD14; 0.40 Po0.001, CD86; 0.18, P ¼ 0.04). Additionally, the expression of CD34 on AML blasts displayed a positive correlation with AML-DC culture outcome (Spearman's r: 0.25; P ¼ 0.007). Likewise, except for CD86 expression, these correlations were also observed with the CI-based culture method (CD120a; 0.23; P ¼ 0.04, CD14; 0.37, Po0.001, CD34; 0.27, P ¼ 0.01). In total, 154 AML samples were used to culture AML-DC by either the cytokine-based culture method or CI-based culture method. It was not always possible to use each AML sample for both culture methods. 147 samples were used in the cytokine-based culture method and 108 samples were used in the CI-based culture method. 
Letters to the Editor
Additionally, the presence of Flt-3 internal tandem duplication (ITD) was examined by reverse transcription-polymerase chain reaction (RT-PCR) with R5 and R6 primers (n ¼ 140). R6 primer was labeled with 6-carboxy-fluorescein (FAM). This primer set covers the transmembrane and juxtamembrane domains of the Flt-3 gene. The length of PCR fragments was determined by capillary electrophoresis on an ABI 3100. In 32% (45/140) of the AML patients a Flt-3 ITD could be detected. Interestingly, the presence of an ITD was strongly correlated with a decreased DC differentiation capacity of AML blasts in the cytokine-based culture method (Spearman's r: À0.42, Po0.001) as well as the CI-based culture method (r: À0.23, P ¼ 0.02). The Flt-3 gene, which encodes a class 3 receptor tyrosine kinase, plays an important role in hematopoiesis. Stimulation of Flt-3 by its ligand, Flt-3L, induces proliferation as well as differentiation of hematopoietic progenitor cells. To increase viability and yield, Flt-3L, as well as SCF and IL-3, are commonly added to DC cultures. In our AML-DC cultures, Flt-3L, SCF and IL-3 were present only during to the first days of culture and upon medium refreshment, each 3-4 days during the culture period, differentiation was stimulated by continuous addition of GM-CSF, TNF-a and IL-4.
Mutations in the Flt-3 gene such as an ITD in the juxtamembrane domain contribute to leukemogenesis by constitutive activation of the receptor. Presence of Flt-3 ITD is correlated with high WBC, increased relapse rates and decreased overall survival. The role of Flt-3 ITD in proliferative and antiapoptotic responses of cells is firmly established.
Interestingly, this study shows that the presence of Flt-3 ITD is strongly associated with decreased DC differentiation inducibility of AML cells in vitro. It has been demonstrated that Flt-3 ITD causes a block in myeloid differentiation in the murine hematopoietic myeloid cell line 32D, which could be overcome by using the Flt-3 kinase inhibitor, CEP-701. Flt-3 ITD signaling represses the expression of two genes required for myeloid differentiation, namely, CCAAT/enhancer binding protein a (C/ EBPa) and PU.1. Inhibition of Flt-3 tyrosine kinase activity was able to reverse this suppression and restore differentiation potential. PU.1, being a down stream target of C/EBPa, has been found to be decisive in controlling the choice of macrophage versus DC development. PU.1 expression was instructive for DC fate in HL60 cells. Hence, we hypothesize that the suppressed expression of C/EBPa and PU.1 in Flt-3 ITD þ AML cells could result in decreased capacity of these cells to differentiate towards DC.
In a multivariate analysis CD120a, CD14, CD86, CD34 and Flt-3 ITD were combined to develop a model by which the DC differentiation capacity of AML blasts can reliably be predicted. In the earliest obtained patient samples not all parameters were measured and therefore unavailable for analysis. In 89 patients all fivr parameters were available for analysis. As assessed by Mann-Whitney U analysis, these 89 patients did not significantly differ from the remaining group concerning known prognostic risk factors such as age, WBC, achievement of CR and cytogenetic risk groups, indicating this group is representative for the total patient group.
Cut off values for CD14 (3.5%), CD86 (4%) and CD34 (59%) were used in the multivariate logistic regression analysis, and were based upon median expression levels (Table 1) . For CD120a, a cutoff value of 15% was used, as described previously. 6 In the multivariate analysis powerful predictors of cytokine-mediated AML-DC culture outcome proved to be Flt-3 ITD (regression coefficient B:-3.41, P ¼ 0.0001), CD14 (B:3.28, P ¼ 0.0001) and CD120a (B:2.82, P ¼ 0.0006). Based upon the three relevant predictors Flt-3 ITD, CD14 and CD120a, cytokine-mediated AML-DC culture outcome can be predicted by the following formula:
Probability ðAML À DC differentiationÞ : Abbreviations: AML-DC, acute myeloid leukaemia-dendritic cell; ITD, internal tandem duplication. The probability that AML blasts will differentiate towards AML-DC can be calculated by the formula presented in the text.
Successful AML-DC differentiation is reflected by calculated probabilities of 74, 76, 84 and 99%. Probabilities of 1, 10, 14 and 16% reflect the impossibility of AML blasts to differentiate into AML-DC. As shown by the receiver operative characteristic curve depicted in Supplementary Figure 1 , high sensitivity and specificity is reached, using this model to predict AML-DC culture outcome (area under the curve ¼ 0.93, Po0.001).
No mutual correlations were found between CD14 expression, CD120a expression and presence of Flt-3 ITD. Previously it was stated that just the CD14 þ AML blast fraction could differentiate towards AML-DC. 7 We showed instead that CD14 À AML blasts could differentiate into AML-DC as well, if CD120a was expressed. 8 In this large patient group these results were confirmed and extended. In the CD14
À group (n ¼ 67), still 39% (26/67) blast samples showed differentiation towards AML-DC. In this subgroup both CD120a and Flt-3 ITD appeared to be significant predictors for culture outcome (B: 2.42, P ¼ 0.01, B: À2.89, P ¼ 0.01, respectively).
Applying the 4 identified parameters in a multivariate analysis to predict AML-DC differentiation in the CI-based method only the presence of a Flt-3 ITD proved to be a significant predictor (B: À0.94, P ¼ 0.04). This culture method provides a successful alternative in 25% of unsuccessful cytokine-based cultures. The percentage increases to 56% if Flt-3 ITD þ AML samples are left out from the analysis, emphasizing Flt-3 ITD þ blasts' inability to differentiate towards leukemic DC. Treatment with CI results in activation of protein kinase C (PKC). PKC blockade abrogates DC differentiation of leukemic blasts. Intriguingly, in case of Flt-3 ITD, PKC is activated and the small molecule Flt-3 ITD inhibitor, PKC412, is able to inhibit tyrosine kinase receptor activity. However, presence of Flt-3 ITD is strongly associated with diminished DC differentiation inducibility of leukemic blasts. Therefore, we suspect other signaling pathways are involved that are responsible for the observed differentiation blockade. The mitogen-activated protein-kinase kinase/extracellular signal-regulated kinase (ERK) cascade might represent such a pathway, as C/EBPa function is inhibited by ERK1/2-mediated phosphorylation in AML blasts carrying Flt-3 activating mutations. 9 Alleviating ERK1/2 activity induced myeloid differentiation in these cells.
AML samples (n ¼ 19) obtained after development of the above-described predictive model were used to analyze quality of the model. Results, shown in Table 2 , indicate that the model based on the expression of CD120a, CD14 and the presence of Flt-3 ITD is consistent in predicting AML-DC differentiation capacity. Only in one AML sample the model predicted AML-DC differentiation culture, whereas in culture AML blasts failed to differentiate. Thus, in a prospective analysis a sensitivity of 100% and specificity of 88% is reached.
In conclusion, AML blast characteristics reliably predict AML-DC culture outcome and thereby enable patient selection for clinical trials. This approach is feasible for the majority of AML patients. A phase I/II trial, applying this approach, is currently conducted at our institution.
